Posted by Michael Wonder on 18 Oct 2020
Novartis receives positive CHMP opinion for Leqvio (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
16 October 2020 - If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolaemia or mixed dyslipidaemia.
Novartis announced today that the CHMP of the EMA has adopted a positive opinion and recommended granting marketing authorisation of Leqvio (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidaemia, marking an important milestone towards it becoming available in the EU.
